Maynard Um
-
-
-
-
-
-
-
CytoSorbents posts flat Q4 revenue of $9.2 million, plans FDA filing
-
-
-
-
-
-
-
Cytosorbents (CTSO) Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorbâ„¢-ATR
-
-
-
-
-
-
-
Cytosorbents (CTSO) Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
-
-
-
-
-
-
-
Cytosorbents (CTSO): FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
-
-
-
-
-
-
-
EF Hutton Starts CytoSorbents (CTSO) at Buy
-
-
448,119 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

